New Test Streamlines Detection of GI Parasites

Genetic Signatures (ASX: GSS) has achieved FDA clearance for its EasyScreen Gastrointestinal Parasite Detection Kit, the broadest molecular syndromic test for eight GI parasites. This innovative test simplifies workflows and provides rapid, reliable results, overcoming the limitations of traditional, labor-intensive methods.

The company plans an immediate US launch, aiming to capture 40% of the $500 million market within five years. Allison Rossiter, an experienced diagnostics executive, will lead the expansion as the new CEO starting September 2024. With robust support from capital raising and an experienced sales team, Genetic Signatures anticipates significant growth and impact in the diagnostics market.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com